Berit Markevarn
Overview
Explore the profile of Berit Markevarn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flygt H, Soderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al.
Leukemia
. 2024 Feb;
38(4):925.
PMID: 38418611
No abstract available.
2.
Flygt H, Soderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al.
Leukemia
. 2024 Jan;
38(4):781-787.
PMID: 38278960
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular...
3.
Geelen I, Gullaksen S, Ilander M, Olssen-Stromberg U, Mustjoki S, Richter J, et al.
Ann Hematol
. 2023 Apr;
102(6):1395-1408.
PMID: 37119314
In order to improve molecular response for a discontinuation attempt in chronic myeloid leukemia (CML) patients in chronic phase, who had not achieved at least a molecular response <0.01% BCR-ABL1...
4.
Huuhtanen J, Ilander M, Yadav B, Dufva O, Lahteenmaki H, Kasanen T, et al.
J Clin Invest
. 2022 Sep;
132(17).
PMID: 36047494
In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising...
5.
Flygt H, Soderlund S, Stentoft J, Richter J, Koskenvesa P, Mustjoki S, et al.
Eur J Haematol
. 2021 Aug;
107(6):617-623.
PMID: 34418168
Objectives: Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of...
6.
Flygt H, Sandin F, Dahlen T, Dremaine A, Lubking A, Markevarn B, et al.
Br J Haematol
. 2021 Mar;
193(5):915-921.
PMID: 33782950
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine,...
7.
Richter J, Lubking A, Soderlund S, Lotfi K, Markevarn B, Sjalander A, et al.
Leukemia
. 2021 Feb;
35(8):2416-2418.
PMID: 33589755
No abstract available.
8.
Kreutzman A, Yadav B, Brummendorf T, Gjertsen B, Lee M, Janssen J, et al.
Oncoimmunology
. 2019 Aug;
8(9):e1638210.
PMID: 31428530
Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal...
9.
Lubking A, Dreimane A, Sandin F, Isaksson C, Markevarn B, Brune M, et al.
Bone Marrow Transplant
. 2019 Apr;
54(11):1764-1774.
PMID: 30962502
Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation...
10.
Rajala H, Missiry M, Ruusila A, Koskenvesa P, Brummendorf T, Gjertsen B, et al.
J Cancer Res Clin Oncol
. 2017 Mar;
143(8):1543-1554.
PMID: 28337541
Purpose: Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied...